Biopharmaceutical company focused on discovering and developing precision oncology therapies for patients with solid tumors.
Erasca, Inc., headquartered in San Diego, California, is a dynamic clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies targeting RAS/MAPK pathway-driven cancers. Established in 2018, Erasca focuses on pioneering treatments that address critical unmet needs in oncology.
At the forefront of Erasca's pipeline are its lead candidates, each designed to target specific molecular pathways implicated in cancer progression. ERAS-007, an oral inhibitor of ERK1/2, shows promise for treating non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia. Additionally, ERAS-601, an oral SHP2 inhibitor, is being developed for patients with advanced or metastatic solid tumors. The company also aims to advance ERAS-801, a central nervous system-penetrant EGFR inhibitor, as a potential therapy for recurrent glioblastoma multiforme.
Erasca distinguishes itself through a robust commitment to scientific innovation and rigorous clinical development. By leveraging deep expertise in molecular biology and oncology, the company aims to deliver transformative therapies that improve outcomes and quality of life for cancer patients globally.
Driven by a vision to redefine the treatment landscape for RAS/MAPK pathway-driven cancers, Erasca collaborates with leading researchers and institutions to accelerate the development of its pipeline. With a focus on precision medicine and therapeutic innovation, Erasca continues to push the boundaries of cancer treatment, aiming to make meaningful advancements in the fight against cancer.